News and Media

advanceCOR announces an exclusive license agreement with MorphoSys for the development and commercialization of anti-GPVI antibodies

Completion of patient recruitment in a clinical phase II study on Revacept

advanceCOR GmbH secures financing for proof of concept patient studies

AdvanceCOR GmbH Has Received Funding from the German Federal Ministry of Education (BMBF) and the Bavarian Research Foundation

AdvanceCOR GmbH closes a second financing round with MIG AG as lead investor

Press release Download

(August 2015)

Press release Revacept Phase II

Press release Download

(April 2013)

Press release financing round

Press release Download

(March 2013)